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In situ photoimmunotherapy (ISPI) can be a treatment option for selected cutaneous malignancies in
patients who are not surgical candidates. We herein report the case of a large, ulcerating poorly
differentiated squamous cell carcinoma (SCC) affecting the foot of an elderly woman with chronic
arsenicosis. The tumor failed radiotherapy, intralesional methotrexate, and 5-aminolevulinic acid
photodynamic therapy (PDT). Because the patient was reluctant to undergo amputation, the recurrent
tumor was treated with ISPI using topical imiquimod application followed by PDT. Despite some initial
improvement in the superﬁcial part of the tumor, tumor invasion to the underlying bone was detected.
This case illustrates the lack of efﬁcacy of ISIP in treating a high-risk invasive SCC.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Squamous cell carcinoma (SCC) in patients with chronic arsenicosis
is believed to be more invasive.1 The treatment of choice is surgical
excision.2 However, alternative treatments may be needed for pa-
tients who cannot tolerate or refuse surgery. Imiquimod is a topical
immune modiﬁer acting mainly by exhibiting agonistic activity
toward Toll-like receptors 7 and 8.3 Initially, it was approved to
treat genital and perianal warts. In recent years, imiquimod has
been used as a safe and effective treatment option for a variety of
skin cancers including actinic keratosis, basal cell carcinoma, SCC in
situ (Bowen’s disease), lentigo maligna, and extramammary Paget’s
disease.4 Although studies of imiquimod in treating invasive SCC
are limited, some case reports showed encouraging outcomes.5e7
For example, Hengge and Schaller5 treated a 65-year-old man
with a 4 cm  3 cm SCC on the temple area. The tumor was treated
by applying 5% imiquimod cream overnight three times a week. At
week 16, the tumor was cured completely, which was alsoy have no ﬁnancial or non-
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iwanese Dermatological Associatioconﬁrmed by a histopathological analysis. There was no tumor
recurrence at the 16-month follow-up examination.5
Photodynamic therapy (PDT) destroys tumor cells by activating
a photosensitizer by a speciﬁc wavelength of light after selective
accumulation of the photosensitizer in cancer cells.8 In situ pho-
toimmunotherapy (ISPI), which comprises PDT and topical imi-
quimod, has shown promising results in patients with highly
aggressive cancers including metastatic melanoma9,10 and angio-
sarcoma.11 A patient with cutaneous metastasizing melanoma
preserved his left foot after ISPI.12 Although there is no report
concerning ISPI in treating invasive SCC, these results encouraged
us to treat our patient with ISPI as a limb-sparing approach.
Case report
An 85-year-old female with chronic arsenicosis visited our clinic in
2005 with an 8-year history of chronic nonhealing ulcer over her
right dorsal foot. A physical examination revealed a large ulcer
(7.2 cm  5 cm; Figure 1A), which proved to be a poorly differen-
tiated SCC with minimal dermal invasion histopathologically. She
refused surgical intervention or chemotherapy but accepted radi-
ation therapy. There was approximately 90% improvement of the
tumor (Figure 1B) with re-epithelization after radiotherapy with a
total dose of 4000 cGy over 4 months. However, local recurrence
with ulceration occurred 3 months later. Both the radiologist and
surgeon suggested amputation but the patient refused. Shen. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A) A large squamous cell carcinoma presented as a chronic ulcer on the dorsal foot of an 85-year-old female. (B) The ulcer reduced by >90% after she received 4000 cGy
over 4 months. (C) The tumor regrew despite repeated photodynamic therapies (PDTs; 660 J/cm2) and intratumoral methrotrexate (62 mg) injections. (D) The tumor improved with
a shallower ulcer and ﬂat edge within a month after 12-day imiquimod occlusion and 120 J/cm2 PDT (in situ photoimmunotherapy or ISPI). (E) The intact metatarsal bone prior to
ISPI. (F) The bone underneath was invaded by the tumor after ISPI. ISPI ¼ in situ photoimmunotherapy; PDT ¼ photodynamic therapy.
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and/or PDT. Since then, she has received weekly or biweekly in-
jections of 0.5 mL intratumoral methotrexate (Emthexate, 25 mg/
mL; ASTA Medica Pty Limited, Auckland, Australasia) and PDT. ThePDT was done by occluding the ulcer with 4% 5-aminolevulinic acid
for 6 hours prior to exposing it to 120 J/cm2 at 120 mW/cm2 red
light (PDT 1200 lamp; Waldmann, Villingen-Schwenningen, Ger-
many).13 The ulcer showed a partial response (Figure 1C) after she
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relapsed soon after. In an attempt to stimulate host immune
response against the tumor, 250mg (5%) imiquimod cream (Aldara;
3M Pharmaceuticals, St. Paul, MN, USA) was evenly applied on the
ulcer, which was subsequently occluded with an air-permeable
water-resistant membrane (Tegaderm; 3M Pharmaceuticals) for
12 hours daily over 12 days. One additional PDT (120 J/cm2) was
performed on Day 6 during imiquimod therapy. She tolerated the
treatments well and the tumor improved clinically (Figure 1D).
Regrettably, a follow-up radiographic examination showed evi-
dence of tumor invasion to the underlying metatarsal bone, which
was intact 5 months prior to ISPI (arrows, Figure 1E and F). She
ﬁnally underwent below the knee amputation and was disease free
at a 4-year follow-up after surgery.
Discussion
It is well documented that both arsenic and human papillomavirus
(HPV) are strong carcinogens in humans. A history of arsenic
exposure and HPV seropositivity were associated with increased
nonmelanoma skin cancer risks.14 However, the mechanisms by
which HPV and arsenic interact remain to be established. Even
though we did not examine HPV titer in this patient, it is of interest
to investigate the role of HPV in skin cancer arising in patient with
chronic arsenicosis.
Topical imiquimod without PDT has shown signiﬁcant efﬁcacy
in treating superﬁcial skin cancers.3 However, there is a risk of
incomplete eradication of the deeper penetrating portion of the
tumor. This can result in the invasion of the underlying bone and
cause bone fracture and bone pain.15 A similar case of SCC invading
the bone of a digit was reported previously.16
ISPI is a new anticancer therapy, which intends to boost the host
immune response against cancer. This is achieved by the activation
of innate and cellular immune responses with imiquimod when
tumor antigens have been generated by tumor cell destructionwith
PDT.3 The tumor antigens are strong and speciﬁc. A systemic im-
mune response speciﬁcally against a distant tumor can be elicited
by treating a tumor locally with PDT and imiquimod. The failure of
ISPI in our patient might be attributed to the following reasons. (1)
The tumor was naturally less responsive to ISPI. (2) The absorption
peak (635 nm) of the photosensitizer protoporphyrin IX, the active
metabolite of 5-aminolevulinic acid, only penetrates the superﬁcial
dermis leaving the deeper part of the tumor untouched. By com-
parison, the infrared absorption peak of indocyanine green used in
treating melanomas can penetrate deeper tissues. The immune
responses elicited by ISPI may depend on the dose and strength of
the antigens generated from tumor destruction. The insufﬁcient
destruction of the tumor might have limited the release of tumor
antigens in our patient. It is well known that tumor antigens of
malignant melanoma are highly immunogenic. Melanoma-
associated vitiligo is the best studied example of the linkage be-
tween tumor immunity and autoimmunity.17 The tumor antigens of
SCC released after ISPI might not be as immunogenic as in mela-
noma. The patient had three small Bowen’s diseases (SCC in situ) on
her trunk. The lesions were treated with cryotherapy and healed
without recurrence prior to ISPI. Otherwise, we could observe thesystemic effects of ISPI. (3) The amount of imiquimod absorbed
might not be sufﬁcient to initiate antitumor immunity. Naylor
et al10 did not quantify the amount of imiquimod they used in ISPI.
Nevertheless, they applied 20 cm2  20 cm2 imiquimod on their
patient’s skin, an area that was approximately three times larger
than our patient.
In conclusion, though ISPI may have signiﬁcant efﬁcacy on the
treatment of metastatic melanoma, physicians should be aware of
the limitations of ISPI in treating aggressive or deeply invasive SCCs
in which the deeply invasive part of the tumor may be beyond the
penetration limit of ISPI despite positive treatment response in the
superﬁcial part of the tumor.
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